News

J A Kemp Appoints Biotechnology and Life Sciences Partner

J A Kemp LLP has appointed Dr Ian MacLeod as a Partner in its London office.

Ian is qualified as a European and UK Chartered Patent Attorney. He joined J A Kemp in January 2020 after working for over ten years at another top tier firm. [Carpmaels & Ransford]

Ian handles a wide range of subject matter in the biotechnological and life sciences field, with particular expertise in bacterial products targeting the microbiome, vaccines, antibody therapeutics, biomarker diagnostics, and antisense nucleotides.

PredictImmune PROFILE trial recruits over 200 patients

Cambridge, UK, 07 January: PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, is pleased to confirm that its PROFILE trial has reached the half way mark in terms of recruitment, having secured over 200 patients.

ERS Genomics announces agreement with New England Biolabs to commercialize CRISPR gene editing tools and reagents

DUBLIN, Ireland, and Ipswich MA, USA, 07 January 2020: ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property (IP) co-owned by Dr. Emmanuelle Charpentier, today announced it has signed an agreement with New England Biolabs (NEB^®), a global leader in the discovery and production of enzymes for molecular biology applications, granting NEB rights to sell CRISPR/Cas9 tools and reagents.

PhoreMost and Boehringer Ingelheim enter multi-project drug discovery collaboration

Cambridge, UK, 07 January 2020: PhoreMost Limited, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has entered into a multi-project drug discovery collaboration with Boehringer Ingelheim, one of the world-leading pharmaceutical companies developing innovative therapies for diseases with unsatisfactory treatments. Under the terms of the agreement, PhoreMost will receive an upfront payment and research funding together with downstream success-based milestones. Further financial terms are not disclosed.

LifeArc ‘Accelerate@Babraham Award’ will give one early-stage life science venture additional cash boost

Cambridge 06 January 2020: Sponsors of the Babraham Research Campus Accelerate@Babraham initiative, LifeArc, has announced the extension of its support, by releasing an additional £10,000 in the form of an award for the most progressed venture currently participating in the StartUPCompetition@Babraham 2019/20 programme.

Webinar: Innovations in viral vector development, scale up and production

Viral vectors have taken a striking importance in the current biomanufacturing landscape, with the unprecedented global need for viral particles creating significant capacity and productivity challenges.

Join our educational webinar and learn how recent innovation can help you to significantly push the boundaries of viral vectors productivity and quality.

Efficient Isolation of Circulating Cell Free DNA

AMSBIO has expanded its range of cfPure™ Cell Free DNA Purification Kits for rapid and efficient isolation of circulating cell free DNA (cfDNA). A new cfPure™Max kit is now available for use on samples of 5mLs volume or greater.

Abcam and SomaServe announce comprehensive partnership to realise the potential of PolyNaut ‘bionic’ nanoparticles for delivery to live cells

Cambridge, UK, – 17 December 2019: Abcam plc, a global innovator in life science reagents and tools, and SomaServe Ltd, a Pharma service and specialist reagent business exploiting PolyNaut^â Technology, have announced a partnership to commercialise the cell delivery potential of the polymer-based ‘bionic’ nanoparticles, which can carry a range of payloads directly to live cells.

BioIVT Announces the Launch of its Next-generation Sequencing Service

Westbury, NY – Dec. 16, 2019 – BioIVT, a leading provider of research models and services for drug and diagnostic development, today launched its Next-generation Sequencing (NGS) Service, which combines the company’s expertise in human tissue procurement, specimen selection, sample preparation and project management with its in-house NGS capabilities. BioIVT now offers both standard and custom NGS services, including sample extraction, library preparation, sequencing and bioinformatics.

Where world-leading research meets global commercial success

The UK Innovation Corridor has a unique ecosystem of talent and commerce, with world-class businesses, universities and R&D centres standing firmly on a heritage of ground-breaking discovery and invention, as shown by a new report released today at the Genesis Conference by the London Stansted Cambridge Consortium.

This makes it the perfect place to start and build an innovation company and invest in place-making.

My Account